Other anti-inflammatory drugs that have been licensed act broadly on the immune system, according to investigators, and so those agents require careful monitoring for side effects.
“The right balance between efficacy and safety profile becomes increasingly more important for a young patient population, who require long-term treatment,” Dr. Stürner and her coauthors wrote. “The results of the SABA trial are promising from this perspective.”
The study was funded in part by Alpinia Laudanum Institute, which supplied the standardized frankincense extract at no charge. Individual authors reported competing interests with Alpinia Laudanum, Biogen, Sanofi Genzyme, Novartis, Merck Serono, and others.
SOURCE: Stürner KH et al. .